Clinical trial results show weight loss drug reduces the risk of heart and liver diseases in people with obesity A new analysis of a large international clinical trial has found that semaglutide, a compound used in weight loss medications Wegovy and Ozempic, significantly reduces the risk of major heart events and lowers fatty liver disease risk in adults with obesity and heart disease. The findings, published in the journal Nature Medicine, highlight the drug’s potential to address multiple health complications linked to obesity. Fatty liver disease, a common condition affecting approximately 40% of adults, is closely tied to obesity, type 2 diabetes, and high blood pressure. It causes inflammation and scarring in the liver, which can progress to cirrhosis, liver failure, or even the need for a liver transplant. The study, led by researchers at Virginia Commonwealth University (VCU) and international collaborators, focused on semaglutide’s effects on both heart and liver health. The research builds on earlier work by VCU hepatologist Arun Sanyal, M.D., who co-authored the “Effect of Semaglutide in Subjects with Non-cirrhotic Non-alcoholic Steatohepatitis” (ESSENCE) trial. That study demonstrated semaglutide’s ability to improve fatty liver disease and reduce heart disease risk factors. The new analysis, based on the “Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity” (SELECT) trial, expands on these findings by examining patients with advanced liver scarring. The SELECT trial involved over 17,000 participants across 41 countries and 804 clinical sites. Patients who received semaglutide injections for two years experienced a notable reduction in major heart events, such as heart-related death, heart attack, or stroke, compared to those receiving a placebo.#novonordisk #semaglutide #ozempic #wegovy #virginia_commonwealth_university
Melissa McCarthy's Transformation Sparks Discussion After Ozempic Weight Loss Rumors Actress and comedian Melissa McCarthy made headlines in early April 2026 when she attended the Fashion Trust U.S. Awards in Los Angeles, drawing widespread attention for a significant physical transformation. Reports indicated she had lost between 75 and 95 pounds, sparking speculation about the methods behind her change. Her presence at the event, where she wore a metallic Emilio Pucci dress, became a focal point of media coverage, with many observers noting her altered appearance compared to previous public appearances. The event’s social media buzz centered on her new look, with comparisons to past photos and discussions about the potential role of medical interventions, including Ozempic, in her weight loss. McCarthy herself has emphasized that her transformation is the result of sustained lifestyle adjustments rather than a single strategy. In interviews and public statements, she has attributed her progress to consistent changes in diet, exercise routines, and daily habits. She has highlighted the importance of discipline and gradual modifications over time, framing her journey as a long-term commitment to health rather than a quick fix. Her approach reportedly includes a balanced diet, regular physical activity, and attention to rest and stress management, all of which are often associated with sustainable wellness practices. The media reaction to her appearance was mixed but largely focused on the visibility of her transformation. Entertainment outlets extensively covered her red carpet moment, with many outlets emphasizing the contrast between her current look and her previous public appearances.#ozempic #kelly_osbourne #melissa_mccarthy #emilio_pucci #fashion_trust_us_awards
Rs 450 to Rs 4,200: Drugmakers rush in to win the business of losing weight India’s obesity drug market is experiencing rapid expansion as pharmaceutical companies compete to capture a growing segment of the healthcare industry. With rising obesity rates and diabetes prevalence, drugmakers are adjusting pricing strategies and launching generic alternatives to meet demand. Analysts predict the market could grow from approximately Rs 1,500 crore today to Rs 8,000 crore by 2030, driven by both brand-name and generic drugmakers entering the space. Novo Nordisk, a leading player in the weight-loss drug market, recently reduced the price of its Wegovy in India by up to 37%, pricing the lowest dose at Rs 10,850 per month. It also introduced Ozempic at Rs 8,800 per month for the 0.25 mg dose. These price cuts have made the drugs more accessible, but experts warn that the influx of generic options could lead to confusion among prescribers and potential misuse. Over 40 Indian pharmaceutical companies are expected to launch more than 50 brands within weeks, according to Reuters. This surge in competition is aimed at addressing the needs of a population projected to have over 440 million overweight or obese adults by 2050. India, the world’s most populous nation, already has the second-highest number of adults with diabetes after China, according to The Lancet and the International Diabetes Federation. The pricing of weight-loss drugs in India varies significantly, with some generics available for as low as Rs 450 per week. A table detailing the prices of major drugs shows: Alkem Labs offers an injection at Rs 450 weekly or Rs 1,800 monthly. Sun Pharma’s injection ranges from Rs 750–900 weekly. Dr. Reddy’s provides the highest monthly price at Rs 4,200 for its injection.#novonordisk #ozempic #wegovy #sun_pharma #alkem_labs
Novo Nordisk's U.S. headquarters faces FDA scrutiny in latest regulatory action Novo Nordisk’s U.S. headquarters in Plainsboro, New Jersey, has been issued a formal FDA warning letter following an inspection that uncovered compliance issues related to postmarketing adverse drug experience (PADE) reporting. The agency’s findings, detailed in the letter, highlight gaps in the company’s procedures for tracking and reporting side effects of its medications, including Ozempic and Wegovy. Novo acknowledged the letter in a public statement, emphasizing its commitment to addressing the concerns and resolving the issues with the FDA. The FDA’s inspection of the Plainsboro site, which serves as Novo’s U.S. operations hub, took place from January 13 to February 7, 2025, as part of a review of the company’s adherence to PADE regulations. During the inspection, the agency identified multiple shortcomings in Novo’s processes for monitoring and reporting adverse events. These included delays in submitting reports to the FDA, the ability to reject or cancel received reports, and insufficient medical review timelines for evaluating adverse events. The FDA also criticized Novo for failing to thoroughly investigate the root causes of these issues, raising concerns about the company’s ability to ensure product safety. In response, Novo stated it has implemented corrective and preventive action plans and has submitted seven updates to the FDA since the initial Form 483 notice was issued on February 7, 2025. The company argued that the warning letter primarily seeks additional details to confirm its compliance efforts and does not reflect any assessment of the quality or safety of its drugs. Anna Windle, head of clinical development at Novo Nordisk U.S.#fda #novonordisk #ozempic #wegovy #plainsboro_new_jersey
FDA Warns Novo Nordisk of Unreported GLP-1 Side Effects The U.S. Food and Drug Administration has sent a warning letter to Novo Nordisk, the Danish pharmaceutical company that produces the weight-loss drugs Ozempic and Wegovy, accusing the firm of failing to report potential side effects linked to its medications. The agency highlighted three patient deaths associated with the drugs, including one case involving a suicide, and stated that Novo Nordisk did not disclose these incidents within the required timeframe. The FDA also criticized the company for not conducting a thorough investigation into the suicide and for not reporting the event to the agency. The warning letter, dated March 11, 2026, underscores concerns about the safety profile of GLP-1 receptor agonists, a class of drugs used to treat type 2 diabetes and obesity. While these medications have been widely prescribed for their effectiveness in weight management, the FDA’s actions highlight growing scrutiny over their long-term risks. The agency emphasized that Novo Nordisk’s failure to comply with reporting requirements could jeopardize patient safety and regulatory oversight. The deaths cited in the warning include a patient who died by suicide, though the FDA did not specify the exact circumstances of the incident. The agency’s statement suggests that the company’s lack of transparency may have contributed to a delayed response to potential safety issues. This comes amid ongoing debates about the broader use of GLP-1 drugs, which have faced criticism for their high cost and potential side effects, including gastrointestinal distress, cardiovascular risks, and mental health concerns. Novo Nordisk, a global leader in diabetes care, has faced increasing pressure from regulators and healthcare professionals to address safety concerns.#fda #novonordisk #ozempic #wegovy #glp_1_receptor_agonists
Hims & Hers Announces Strategic Shift for US Weight Loss Business Hims & Hers Health, Inc. (NYSE: HIMS) has announced a strategic collaboration with Novo Nordisk to realign its US weight loss offerings with global strategies, focusing on expanding access to FDA-approved GLP-1 medications. The company plans to provide US customers with a broader range of FDA-approved treatments, including compounded semaglutide on a limited scale, while aligning its domestic and international models to position itself as the largest global platform for affordable, approved weight loss medications. The US weight loss market has evolved significantly since Hims & Hers entered the space in 2023. Advances in the industry have led to greater availability of FDA-approved GLP-1 treatments at more affordable prices, with improved dosing flexibility and diverse delivery formats, driving increased demand for branded, regulated medications. As part of this shift, Hims & Hers will discontinue advertising compounded GLP-1 products on its platform or in marketing materials. Existing patients will be transitioned to FDA-approved medications when clinically appropriate, though limited access to compounded GLP-1s will remain available for patients whose needs cannot be met by commercially available options. The partnership with Novo Nordisk will bring Ozempic® (semaglutide) in various dosages, including injectable and pill forms, to the platform later this month. Over time, Hims & Hers will educate customers on their treatment options and support seamless transitions to FDA-approved medications as determined by healthcare providers. The companies aim to expand their collaboration to include additional products as they become available, enhancing the range of treatments available to providers.#semaglutide #hims_hers_health #novo_nordisk #glp_1 #ozempic
